Impetigo

Summary

Impetigo (MONDO:0004592) is a disease and 22 clinical trials. Top therapeutic interventions include mupirocin, retapamulin, and ozenoxacin. A subtype of pyoderma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 22

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	impetigo
Mondo ID	MONDO:0004592
MeSH	D007169
DOID	DOID:8504
ICD-10-CM	L01, L01.0
ICD-11	971176543
NCIT	C99088
SNOMED CT	48277006
UMLS	C0021099
MedGen	9440
Is cancer (heuristic)	no

Disease family

This is a subtype of pyoderma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › pyoderma › impetigo

Related subtypes (4): cutaneous diphtheria, carbuncle, erythrasma, pyoderma gangrenosum

Subtypes (2): ecthyma, impetigo herpetiformis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

3 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Mupirocin	Approved (phase 4)
Ozenoxacin	Approved (phase 4)
Retapamulin	Approved (phase 4)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Minocycline.

Clinical trials & evidence

Clinical trials

Clinical trials: 22.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE2	5
PHASE3	4
PHASE4	3
PHASE2/PHASE3	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00986856	PHASE4	TERMINATED	Fucidin® Cream in the Treatment of Impetigo
NCT01126268	PHASE4	COMPLETED	Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection
NCT02775617	PHASE4	COMPLETED	Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
NCT00133848	PHASE3	COMPLETED	Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment
NCT01397461	PHASE3	COMPLETED	Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
NCT01611909	PHASE2/PHASE3	UNKNOWN	Citriodiol® and Impetigo
NCT01670032	PHASE2/PHASE3	COMPLETED	Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo
NCT02090764	PHASE3	COMPLETED	Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo
NCT04287777	PHASE3	COMPLETED	Safety and Efficacy of Mupirocin Gel in Children With Impetigo
NCT00626795	PHASE2	COMPLETED	Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)
NCT00758862	PHASE2	COMPLETED	The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo
NCT01171326	PHASE2	COMPLETED	Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients
NCT01367314	PHASE2	COMPLETED	Safety and Efficacy of Topical NVC-422 Gel in Impetigo
NCT03429595	PHASE2	COMPLETED	Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo
NCT01943136	PHASE1	UNKNOWN	The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial
NCT07093749	Not specified	RECRUITING	Perspectives on Antibiotics and Tracking Symptoms in Children
NCT00884728	Not specified	COMPLETED	Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia’s Northern Territory
NCT01153828	Not specified	COMPLETED	EU PV for Retapamulin-Prescribing
NCT02902822	Not specified	COMPLETED	Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
NCT03177993	Not specified	COMPLETED	Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji
NCT05226260	Not specified	COMPLETED	Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care
NCT07428915	Not specified	COMPLETED	Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MUPIROCIN	4	3
RETAPAMULIN	4	3
OZENOXACIN	4	2
AZITHROMYCIN	4	1
FUSIDIC ACID	4	1
IVERMECTIN	4	1
PERMETHRIN	4	1
AURICLOSENE	2	1
CHEMBL4755088	0	3
CHEMBL5282170	0	3
CHEMBL4793658	0	3
CHEMBL263291	0	1
CHEMBL4082099	0	1
CHEMBL4299381	0	1
CHEMBL4788951	0	1
CHEMBL134350	0	1